New Multimodal Algorithm Highlights Predictive
Benefit Of Artificial Intelligence (AI) for Cancer Research
BOSTON and ROLLE, Switzerland, March 15,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a
cloud-native software company and a leader in data-driven
medicine, and the French Kidney Cancer Research Network
(UroCCR) collaborated on a study using a multimodal algorithm to
help predict post-operative outcomes for those facing renal cell
carcinoma (RCC), with the results recently published in npj
Precision Oncology. The findings of the study showed the
artificial intelligence (AI) model co-constructed by SOPHiA
GENETICS and UroCCR provided a strong prediction for post-operative
outcomes when compared to usual prognostic scores. This publication
follows a prior collaboration that demonstrated the value of
multimodal analysis on pre-operative kidney cancer upstaging.
UroCCR is one of the world's largest collaborative kidney cancer
networks with 51 multidisciplinary clinical teams across
France. In close relationship with
the French Association of Urology (AFU), the goal of UroCCR is to
connect a national, multidisciplinary network of medical and
scientific professionals who focus on therapeutic management and
applied research into kidney cancer. In 2021, UroCCR partnered with
SOPHiA GENETICS to develop an AI-based model to predict whether
kidney cancer will progress from a localized tumor after
surgery.
The UroCCR database provided multimodal, real-world data,
including radiological, clinical, and biological data from more
than 3,300 patients across France
operated between May 2000 and
January 2020. Researchers applied
SOPHiA GENETICS' proprietary AI offering to analyze the data into
easily visualized, reliable predictions that were measured against,
and outperformed most common risk scores.
"The volume and complexity of available health data continues to
increase, and while this can assist in personalized diagnostics and
treatment, it is most effective when paired with AI," said
Thierry Colin, VP, Multimodal
Research and Development, SOPHiA GENETICS. "Our work with UroCCR
over the last three years has significantly advanced its research
of RCC and shown the power of AI to provide insights from
real-world multimodal data. We are extremely pleased with the
findings from this study and look forward to continued
collaboration with UroCCR."
SOPHiA GENETICS' technology and global decentralized network are
designed to break data silos and empower researchers with
data-driven insights to drive the use of precision medicine. The
study from UroCCR and SOPHiA GENETICS shows that an AI-based
prediction model has the potential to support clinical treatment
decision-making and provide an indication of which patients may
potentially benefit from adjuvant systemic therapy, versus those
that can sustain with surveillance.
"At UroCCR, our research is centered on the idea that a shared
database helps facilitate and expand the use of precision medicine
for patients facing kidney cancer," said Pr Jean-Christophe
Bernhard, M.D., PhD., Urologic Surgeon at CHU Bordeaux and head of
the UroCCR. "Our work with SOPHiA GENETICS and the results of our
latest study demonstrated the benefits of using AI to analyze
real-world multimodal data. SOPHiA GENETICS' technology and network
have been key to the success of our research and will be imperative
as we continue progressing with increased data inputs."
UroCCR was created in 2011 and was funded and labeled by the
French National Cancer Institute (INCa) as one of the fourteen
official nationwide clinical and biological databases (BCB). The
network makes it possible to identify and document clinical,
biological, and radiological data – in a shared database – for all
newly diagnosed patients in participating centers. The network has
been referenced in 2023 by the High Authority on Health (HAS) as
real-life data provider of interest. For more information connect
on X and LinkedIn.
The SOPHiA DDM™ Platform has the ability to analyze
multimodal data due to its cloud-based AI-driven environment that
integrates and standardizes diverse data modalities to fuel the
development of predictive models capable of addressing research
questions. For more information on the collaboration between
SOPHiA GENETICS and UroCCR, visit SOPHiAGENETICS.com and
UroCCR.fr.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products, and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/sophia-genetics-and-the-french-kidney-cancer-research-network-uroccr-publish-results-from-multiyear-collaboration-302090011.html